Täby, Sweden

Roger Emanuel Rönn

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Amniotics Ab. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Roger Emanuel Rönn

Introduction

Roger Emanuel Rönn is a notable inventor based in Täby, Sweden. He has made significant contributions to the field of hematopoietic cell generation. His work focuses on enhancing the efficiency of blood cell production from reprogrammed cells or pluripotent stem cells.

Latest Patents

Roger Rönn holds a patent for "Methods and compositions for generating hematopoietic cells." This patent describes how maturation signals provided via cyclic adenosine monophosphate (cAMP) and Epac signaling can improve the function of hematopoietic cells differentiated from stem cells. The cAMP/Epac signaling pathway increases the efficiency of producing precursors to blood and blood cells. These generated blood cells have potential applications in therapeutics, treatments, disease prevention, drug discovery, personalized medicine, regenerative medicine, and universal donor banks.

Career Highlights

Roger Rönn is associated with Amniotics AB, where he continues to advance his research and innovations. His work has the potential to revolutionize the field of regenerative medicine and improve patient outcomes.

Collaborations

Some of his notable coworkers include Shobhit Saxena and Niels-Bjarne Roland Woods. Their collaborative efforts contribute to the ongoing research and development in the field of hematopoietic cell generation.

Conclusion

Roger Emanuel Rönn's innovative work in hematopoietic cell generation showcases the potential of stem cell research in medicine. His contributions are paving the way for advancements in therapeutic applications and personalized medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…